Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.14% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIK · Sep 30, 2024
Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001171843-24-005993General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
12.94% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
-6.54% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
102.26% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
3.72% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-72.30% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
18.69% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
8.76% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 8.12%
- Current
- 3.14%
- Delta
- -4.98%
- Previous
- -2.55%
- Current
- 12.94%
- Delta
- 15.49%
- Previous
- -5.37%
- Current
- -6.54%
- Delta
- -1.17%
- Previous
- 122.76%
- Current
- 102.26%
- Delta
- -20.50%
- Previous
- 65.28%
- Current
- 3.72%
- Delta
- -61.56%
- Previous
- 0.38%
- Current
- -72.30%
- Delta
- -72.68%
- Previous
- 17.65%
- Current
- 18.69%
- Delta
- 1.05%
- Previous
- 9.28%
- Current
- 8.76%
- Delta
- -0.52%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_DECREASED →Transitioned To · ANIK CASH_GENERATION_INCREASED →Transitioned To · ANIK GROWTH_DECREASED →Transitioned To · ANIK INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIK MARGIN_DECREASED →Transitioned To · ANIK PROFITABILITY_DECREASED →Transitioned To · ANIK R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIK SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.